A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as galunisertib administered in combination with the anti-programmed cell death-ligand 1 (PD-L1) antibody, durvalumab, in participants with refractory metastatic pancreatic cancer.
The results of this study are not yet available.
The duration of your participation depends on how well your disease responds to the study treatment.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participants must have metastatic pancreatic cancer, confirmed by histology or cystology. Recurrence must be documented by diagnostic biopsy.
Participants must have had disease progression, been resistant, or intolerant to no more than 2 prior systemic regiments for locally advanced or metastatic pancreatic cancer.
Participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received 1 of the following treatments for their metastatic disease: FOLFIRINOX, nanoparticle albumin-bound paclitaxel/gemcitabine, TS-1 (tegafur gimeracil oteracil potassium), irinotecan liposome injection/5-fluorouracil (5FU)/Leucovorin or single-agent gemcitabine prior to entering the study
For some parts of the study, participants must be willing to undergo a tumor biopsy or to provide an available archival tumor sample
Participants must use approved contraceptive methods
Participants must not have moderate or severe cardiovascular disease